RecruitingPhase 2NCT06559826

Ketamine-Assisted Psychotherapy (KAP) Compared to Ketamine Alone for the Treatment of Depression

Studying Mal de débarquement

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Icahn School of Medicine at Mount Sinai
Principal Investigator
James Murrough, MD, PhD
Icahn School of Medicine at Mount Sinai
Intervention
Ketamine(drug)
Enrollment
70 target
Eligibility
18-90 years · All sexes
Timeline
20252027

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06559826 on ClinicalTrials.gov

Other trials for Mal de débarquement

Additional recruiting or active studies for the same condition.

See all trials for Mal de débarquement

← Back to all trials